8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Apr 3, 2026·SEC
Material company update
Mar 26, 2026·SEC
Rhythm Pharmaceuticals, Inc.(RYTM)Earnings, Financials & Key Ratios
RYTM•NASDAQ
$92.31
$6.3B mkt cap·Price updated May 6, 2026
AboutRhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Show more
- Revenue$190M+45.8%
- EBITDA-$191M+27.8%
- Net Income-$197M+24.6%
- EPS (Diluted)-3.11+28.3%
- Gross Margin89.73%
- EBITDA Margin-100.49%+50.5%
- Operating Margin-101.19%+50.4%
- Net Margin-103.57%+48.3%
- ROE-129.46%+17.0%
- ROIC-70.15%+66.5%
- Debt/Equity1.77+7305.6%
- Interest Coverage-8.52+26.7%
RYTM Key Insights
Rhythm Pharmaceuticals, Inc. (RYTM) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Negative free cash flow
- ✗Expensive at 43.1x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
RYTM Price & Volume
Rhythm Pharmaceuticals, Inc. (RYTM) stock price & volume — 10-year historical chart
Loading chart...
RYTM Growth Metrics
Rhythm Pharmaceuticals, Inc. (RYTM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years100.23%
TTM58.67%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-20.8%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-13%
Return on Capital
10 Years-67.45%
5 Years-69.17%
3 Years-71.38%
Last Year-58.9%
RYTM Recent Earnings
Rhythm Pharmaceuticals, Inc. (RYTM) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 4/12 qtrs (33%)
Q2 2026Latest
May 5, 2026EPS
$0.83
Est $0.86
+3.5%
Revenue
$60M
Est $56M
+7.8%
Q1 2026
Feb 26, 2026EPS
$0.73
Est $0.79
+7.6%
Revenue
$57M
Est $56M
+1.9%
Q4 2025
Nov 4, 2025EPS
$0.82
Est $0.72
-13.9%
Revenue
$51M
Est $56M
-8.4%
Q3 2025
Aug 5, 2025EPS
$0.75
Est $0.66
-13.6%
Revenue
$49M
Est $51M
-5.5%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.83vs $0.86+3.5% | $60Mvs $56M+7.8% |
| Q1 2026 | Feb 26, 2026 | $0.73vs $0.79+7.6% | $57Mvs $56M+1.9% |
| Q4 2025 | Nov 4, 2025 | $0.82vs $0.72-13.9% | $51Mvs $56M-8.4% |
| Q3 2025 | Aug 5, 2025 | $0.75vs $0.66-13.6% | $49Mvs $51M-5.5% |
Based on last 12 quarters of dataView full earnings history →
RYTM Peer Comparison
Rhythm Pharmaceuticals, Inc. (RYTM) competitors in Metabolic and Obesity Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 HALO | 7.76B | 65.87 | 25.73 | 37.55% | 22.69% | 6.49% | 8.31% | |
 RARE | 2.46B | 25.01 | -4.29 | 20.13% | -85.54% | -9.11% | ||
 FOLD | 4.47B | 14.49 | -80.50 | 32.29% | -2.35% | -6.1% | 2.29 | |
 ACMR | 3.5B | 52.80 | 38.54 | 15.24% | 10.44% | 6.11% | 0.16 | |
 PTCT | 5.39B | 65.04 | 8.36 | 114.51% | 39.44% | 13.02% | ||
 KRYS | 8.38B | 284.57 | 41.60 | 33.94% | 53.92% | 19.25% | 2.26% | 0.01 |
 VNDA | 436.72M | 7.39 | -1.98 | 8.72% | -39.7% | -18.07% | 0.02 | |
 MDGL | 11.41B | 502.47 | -39.10 | 432.05% | -39.04% | -46.21% | 0.00 |
Compare RYTM vs Peers
Rhythm Pharmaceuticals, Inc. (RYTM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
RYTM Income Statement
Rhythm Pharmaceuticals, Inc. (RYTM) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 3.15M | 23.64M | 77.43M | 130.13M | 189.76M | 217.16M |
| Revenue Growth % | - | - | - | - | - | 649.46% | 227.56% | 68.06% | 45.83% | 58.67% |
| Cost of Goods Sold | 223K | 442K | 834K | 690K | 599K | 2.13M | 9.3M | 13.37M | 19.49M | 23M |
| COGS % of Revenue | - | - | - | - | 18.99% | 9.02% | 12.01% | 10.27% | 10.27% | - |
| Gross Profit | -223K▲ 0% | -442K▼ 98.2% | -834K▼ 88.7% | -690K▲ 17.3% | 2.56M▲ 470.3% | 21.5M▲ 741.7% | 68.13M▲ 216.8% | 116.76M▲ 71.4% | 170.26M▲ 45.8% | 194.16M▲ 0% |
| Gross Margin % | - | - | - | - | 81.01% | 90.98% | 87.99% | 89.73% | 89.73% | 89.41% |
| Gross Profit Growth % | -54.86% | -98.21% | -88.69% | 17.27% | 470.29% | 741.68% | 216.79% | 71.39% | 45.83% | - |
| Operating Expenses | 32.41M | 78.42M | 145.17M | 135.88M | 172.61M | 200.66M | 252.48M | 382.26M | 362.28M | 391.54M |
| OpEx % of Revenue | - | - | - | - | 5472.86% | 848.9% | 326.09% | 293.76% | 190.92% | - |
| Selling, General & Admin | 9.52M | 28.08M | 36.55M | 46.13M | 68.49M | 92.03M | 117.53M | 144.3M | 194.94M | 219.44M |
| SG&A % of Revenue | - | - | - | - | 2171.4% | 389.34% | 151.8% | 110.9% | 102.73% | - |
| Research & Development | 22.89M | 50.34M | 109.45M | 90.45M | 104.13M | 108.63M | 134.95M | 237.96M | 167.34M | 172.09M |
| R&D % of Revenue | - | - | - | - | 3301.46% | 459.56% | 174.29% | 182.87% | 88.19% | - |
| Other Operating Expenses | 0 | 0 | -834K | -690K | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -32.41M▲ 0% | -78.42M▼ 141.9% | -146M▼ 86.2% | -136.57M▲ 6.5% | -170.06M▼ 24.5% | -179.16M▼ 5.3% | -184.36M▼ 2.9% | -265.5M▼ 44.0% | -192.02M▲ 27.7% | -197.37M▲ 0% |
| Operating Margin % | - | - | - | - | -5391.85% | -757.92% | -238.1% | -204.04% | -101.19% | -90.89% |
| Operating Income Growth % | -25.12% | -141.94% | -86.18% | 6.46% | -24.52% | -5.35% | -2.9% | -44.02% | 27.68% | - |
| EBITDA | -32.19M | -77.97M | -145.17M | -135.88M | -168.9M | -177.49M | -182.6M | -263.94M | -190.68M | -196.42M |
| EBITDA Margin % | - | - | - | - | -5355.14% | -750.85% | -235.83% | -202.83% | -100.49% | -90.45% |
| EBITDA Growth % | -24.95% | -142.24% | -86.17% | 6.39% | -24.3% | -5.08% | -2.88% | -44.55% | 27.76% | -14.81% |
| D&A (Non-Cash Add-back) | 223K | 442K | 834K | 690K | 1.16M | 1.67M | 1.76M | 1.56M | 1.34M | 955K |
| EBIT | -32.41M | -78.42M | -146M | -136.57M | -69.61M | -175.92M | -170.22M | -239.65M | -175.46M | -131.45M |
| Net Interest Income | 0 | 0 | 5.27M | 2.58M | 447K | -1.17M | 53K | -5.89M | -5.29M | -3.52M |
| Interest Income | 566K | 4.35M | 5.27M | 2.58M | 447K | 4.03M | 13.95M | 14.71M | 15.29M | 15.21M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 5.2M | 13.89M | 20.6M | 20.58M | 10.59M |
| Other Income/Expense | -1.3M | 4.35M | 5.27M | 2.58M | 100.45M | -1.96M | 243K | 5.25M | -4.03M | -4.34M |
| Pretax Income | -33.71M▲ 0% | -74.06M▼ 119.7% | -140.73M▼ 90.0% | -134M▲ 4.8% | -69.61M▲ 48.0% | -181.12M▼ 160.2% | -184.11M▼ 1.7% | -260.26M▼ 41.4% | -196.04M▲ 24.7% | -201.72M▲ 0% |
| Pretax Margin % | - | - | - | - | -2207.1% | -766.22% | -237.79% | -200% | -103.31% | -92.89% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 564K | 346K | 497K | 962K |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | -0.31% | -0.13% | -0.25% | -0.48% |
| Net Income | -33.71M▲ 0% | -74.06M▼ 119.7% | -134.62M▼ 81.8% | -130.73M▲ 2.9% | -69.61M▲ 46.8% | -181.12M▼ 160.2% | -184.68M▼ 2.0% | -260.6M▼ 41.1% | -196.54M▲ 24.6% | -203.78M▲ 0% |
| Net Margin % | - | - | - | - | -2207.1% | -766.22% | -238.52% | -200.27% | -103.57% | -93.84% |
| Net Income Growth % | -30.29% | -119.72% | -81.77% | 2.89% | 46.75% | -160.18% | -1.97% | -41.11% | 24.58% | -20.8% |
| Net Income (Continuing) | -33.71M | -74.06M | -140.73M | -134M | -69.61M | -181.12M | -184.68M | -260.6M | -196.54M | -203.78M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.26▲ 0% | -2.39▼ 89.7% | -3.70▼ 54.8% | -2.96▲ 20.0% | -1.37▲ 53.7% | -3.51▼ 156.2% | -3.20▲ 8.8% | -4.34▼ 35.6% | -3.11▲ 28.3% | -3.00▲ 0% |
| EPS Growth % | 18.71% | -89.68% | -54.81% | 20% | 53.72% | -156.2% | 8.83% | -35.63% | 28.34% | -13% |
| EPS (Basic) | -1.26 | -2.39 | -3.70 | -2.96 | -1.37 | -3.51 | -3.20 | -4.34 | -3.11 | - |
| Diluted Shares Outstanding | 26.73M | 31M | 36.42M | 44.13M | 49.6M | 52.12M | 57.67M | 60.99M | 64.98M | 67.97M |
| Basic Shares Outstanding | 26.73M | 31M | 36.42M | 44.13M | 49.6M | 52.12M | 57.67M | 60.99M | 64.98M | 67.97M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
RYTM Balance Sheet
Rhythm Pharmaceuticals, Inc. (RYTM) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 150.67M | 258.69M | 302.4M | 181.67M | 308.39M | 354.24M | 308.27M | 374.2M | 466.92M | 430.09M |
| Cash & Short-Term Investments | 148.08M | 252.06M | 292.46M | 172.79M | 294.86M | 333.29M | 275.85M | 320.56M | 388.95M | 340.63M |
| Cash Only | 34.24M | 49.54M | 62.29M | 100.85M | 59.25M | 127.68M | 60.08M | 89.14M | 54.3M | 62.14M |
| Short-Term Investments | 113.85M | 202.52M | 230.16M | 71.94M | 235.61M | 205.61M | 215.76M | 231.43M | 334.65M | 278.49M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 1.02M | 6.22M | 14.87M | 18.51M | 26.08M | 34.19M |
| Days Sales Outstanding | - | - | - | - | 118.62 | 96.11 | 70.08 | 51.93 | 50.17 | 50.18 |
| Inventory | 0 | 0 | 0 | 0 | 111K | 2.92M | 8.62M | 18.74M | 25.75M | 28.65M |
| Days Inventory Outstanding | - | - | - | - | 67.64 | 499.16 | 338.4 | 511.7 | 482.24 | 290.7 |
| Other Current Assets | 1.06M | 1.34M | 3.51M | 3.05M | 3.99M | 7.42M | 6.67M | 8.8M | 9.97M | 26.62M |
| Total Non-Current Assets | 1.06M | 1.52M | 6.12M | 5.41M | 21.14M | 28.25M | 24.48M | 18.07M | 14.28M | 12.23M |
| Property, Plant & Equipment | 840K | 1.12M | 5.72M | 5M | 4.33M | 3.38M | 2.12M | 4.11M | 4.15M | 4M |
| Fixed Asset Turnover | - | - | - | - | 0.73x | 7.00x | 36.49x | 31.67x | 45.69x | 74.16x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 4.66M | 7.88M | 7.03M | 6.17M | 5.32M | 5.11M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 522K | 1.19M |
| Other Non-Current Assets | 225K | 401K | 403K | 403K | 12.14M | 16.98M | 15.33M | 7.79M | 3.29M | 15.02M |
| Total Assets | 151.74M▲ 0% | 260.21M▲ 71.5% | 308.52M▲ 18.6% | 187.07M▼ 39.4% | 329.52M▲ 76.1% | 382.48M▲ 16.1% | 332.75M▼ 13.0% | 392.27M▲ 17.9% | 481.19M▲ 22.7% | 442.32M▲ 0% |
| Asset Turnover | - | - | - | - | 0.01x | 0.06x | 0.23x | 0.33x | 0.39x | 0.48x |
| Asset Growth % | 1129.73% | 71.49% | 18.57% | -39.37% | 76.15% | 16.07% | -13% | 17.89% | 22.67% | 74.08% |
| Total Current Liabilities | 6.72M | 13.58M | 24.42M | 17.99M | 43.43M | 39.81M | 55.2M | 115.52M | 105.94M | 103.2M |
| Accounts Payable | 2.43M | 7.64M | 10.41M | 4.9M | 5.74M | 4.8M | 4.88M | 12.33M | 13.95M | 12.3M |
| Days Payables Outstanding | 3.97K | 6.31K | 4.56K | 2.59K | 3.5K | 820.87 | 191.68 | 336.6 | 261.17 | 221.6 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7.95M | 676K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 7M | 1.43M | 1.29M | 1.29M | 194K | 242K |
| Other Current Liabilities | 101K | 60K | 377K | 180K | 800K | 2.42M | 5.41M | 43.59M | 61.42M | 102.47M |
| Current Ratio | 22.42x | 19.05x | 12.38x | 10.10x | 7.10x | 8.90x | 5.58x | 3.24x | 4.41x | 4.41x |
| Quick Ratio | 22.42x | 19.05x | 12.38x | 10.10x | 7.10x | 8.83x | 5.43x | 3.08x | 4.16x | 4.16x |
| Cash Conversion Cycle | - | - | - | - | -3.31K | -225.6 | 216.8 | 227.03 | 271.24 | 119.28 |
| Total Non-Current Liabilities | 228K | 372K | 3.09M | 2.55M | 1.95M | 78.41M | 107.78M | 112.21M | 236.18M | 101.5M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 235.19M | 3.16M |
| Capital Lease Obligations | 0 | 0 | 3.09M | 2.55M | 1.95M | 1.26M | 490K | 3.94M | 3.34M | 10.54M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 998K | 998K |
| Other Non-Current Liabilities | 228K | 372K | 0 | 0 | 0 | 77.15M | 107.29M | 108.27M | -3.34M | 198.41M |
| Total Liabilities | 6.95M | 13.95M | 27.5M | 20.55M | 45.37M | 118.22M | 162.99M | 227.72M | 342.13M | 204.7M |
| Total Debt | 0 | 0 | 3.56M | 3.09M | 2.55M | 1.94M | 1.26M | 3.94M | 246.47M | 3.84M |
| Net Debt | -34.24M | -49.54M | -58.74M | -97.77M | -56.7M | -125.73M | -58.82M | -85.2M | 192.17M | -58.3M |
| Debt / Equity | - | - | 0.01x | 0.02x | 0.01x | 0.01x | 0.01x | 0.02x | 1.77x | 1.77x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.02x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.30x |
| Interest Coverage | - | - | - | - | - | -33.82x | -12.25x | -11.63x | -8.52x | -12.41x |
| Total Equity | 144.79M▲ 0% | 246.26M▲ 70.1% | 281.02M▲ 14.1% | 166.53M▼ 40.7% | 284.15M▲ 70.6% | 264.26M▼ 7.0% | 169.76M▼ 35.8% | 164.55M▼ 3.1% | 139.07M▼ 15.5% | 122.91M▲ 0% |
| Equity Growth % | 1884.21% | 70.08% | 14.12% | -40.74% | 70.63% | -7% | -35.76% | -3.07% | -15.48% | -149.3% |
| Book Value per Share | 5.42 | 7.94 | 7.72 | 3.77 | 5.73 | 5.07 | 2.94 | 2.70 | 2.14 | 1.81 |
| Total Shareholders' Equity | 144.79M | 246.26M | 281.02M | 166.53M | 284.15M | 264.26M | 169.76M | 164.55M | 139.07M | 122.91M |
| Common Stock | 27K | 34K | 44K | 44K | 50K | 56K | 59K | 61K | 67K | 69K |
| Retained Earnings | -110.25M | -184.6M | -325.33M | -459.33M | -528.94M | -710.06M | -894.74M | -1.16B | -1.35B | -1.41B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 49K | -1K | -92K | 134K | -39K | -796K | 444K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RYTM Cash Flow Statement
Rhythm Pharmaceuticals, Inc. (RYTM) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -29.46M | -62.06M | -122.75M | -121.98M | -146M | -173.43M | -136.16M | -113.88M | -115.67M | -115.67M |
| Operating CF Margin % | - | - | - | - | -4629.14% | -733.68% | -175.85% | -87.51% | -60.96% | - |
| Operating CF Growth % | -26.88% | -110.64% | -97.81% | 0.63% | -19.69% | -18.78% | 21.49% | 16.36% | -1.58% | -29.99% |
| Net Income | -33.71M | -74.06M | -140.73M | -134M | -69.61M | -181.12M | -184.68M | -260.6M | -196.54M | -203.78M |
| Depreciation & Amortization | 223K | 442K | 834K | 690K | 1.16M | 1.67M | 1.76M | 1.56M | 1.34M | 1.21M |
| Stock-Based Compensation | 2.28M | 6.39M | 11.88M | 17.45M | 20.8M | 19.83M | 32.55M | 39.68M | 66.82M | 77.06M |
| Deferred Taxes | 1.86M | 0 | 0 | 0 | -100M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -76K | 4.51M | 203K | -234K | -250K | 5.91M | 9.4M | 94.9M | 13.68M | -928K |
| Working Capital Changes | -39K | 667K | 5.07M | -5.89M | 1.9M | -19.72M | 4.81M | 10.57M | -968K | 6.94M |
| Change in Receivables | 0 | 0 | 0 | 0 | -1.25M | -5.2M | -8.64M | -3.65M | -7.57M | -16.37M |
| Change in Inventory | 0 | 0 | 0 | 0 | -11K | -2.81M | -5.71M | -10.12M | -7.47M | -9.98M |
| Change in Payables | 1.95M | 6.95M | 10.51M | -6.45M | 18.31M | 1.54M | 14.77M | 21.92M | 21.89M | 19.91M |
| Cash from Investing | -110.04M | -87.15M | -27.97M | 158.53M | -62.16M | 28.03M | -5.67M | -48.17M | -137.15M | -104.91M |
| Capital Expenditures | -133K | -722K | -3.38M | -214K | -5.43M | -4.28M | -47K | 0 | -953K | -953K |
| CapEx % of Revenue | - | - | - | - | 172.29% | 18.11% | 0.06% | - | 0.5% | - |
| Acquisitions | 0 | 0 | 24.59M | 0 | 100M | 4M | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -109.91M | -86.43M | -24.59M | 0 | 7M | -4M | -5.67M | -40.5M | -40M | -40M |
| Cash from Financing | 167.2M | 164.69M | 163.47M | 2.01M | 166.48M | 213.83M | 74.37M | 191.24M | 217.96M | 180.06M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -12.9M | -19.92M | -5.4M |
| Equity Issued (Net) | 166.5M | 162.88M | 161.35M | 0 | 161.73M | 131.11M | 48.88M | 195.24M | 237.88M | 191.11M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -3.97M | -5.38M | -1.11M |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 700K | 1.81M | 2.12M | 2.01M | 4.75M | 82.72M | 25.49M | 12.87M | 5.38M | -4.53M |
| Net Change in Cash | 27.7M▲ 0% | 15.48M▼ 44.1% | 12.75M▼ 17.6% | 38.56M▲ 202.3% | -41.68M▼ 208.1% | 68.43M▲ 264.2% | -67.6M▼ 198.8% | 29.19M▲ 143.2% | -34.78M▼ 219.1% | -43.82M▲ 0% |
| Free Cash Flow | -29.59M▲ 0% | -62.78M▼ 112.1% | -126.14M▼ 100.9% | -122.19M▲ 3.1% | -151.44M▼ 23.9% | -177.71M▼ 17.3% | -136.2M▲ 23.4% | -113.88M▲ 16.4% | -116.63M▼ 2.4% | -120.46M▲ 0% |
| FCF Margin % | - | - | - | - | -4801.43% | -751.79% | -175.91% | -87.51% | -61.46% | -55.47% |
| FCF Growth % | -21.9% | -112.14% | -100.92% | 3.12% | -23.93% | -17.35% | 23.36% | 16.39% | -2.41% | -6.15% |
| FCF per Share | -1.11 | -2.02 | -3.46 | -2.77 | -3.05 | -3.41 | -2.36 | -1.87 | -1.79 | -1.79 |
| FCF Conversion (FCF/Net Income) | 0.87x | 0.84x | 0.91x | 0.93x | 2.10x | 0.96x | 0.74x | 0.44x | 0.59x | 0.59x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RYTM Key Ratios
Rhythm Pharmaceuticals, Inc. (RYTM) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -44.33% | -37.88% | -51.06% | -58.42% | -30.89% | -66.05% | -85.1% | -155.91% | -129.46% | -204.35% |
| Return on Invested Capital (ROIC) | -43.68% | -38.28% | -52.27% | -70.39% | -86.12% | -73.43% | -110.85% | -209.29% | -70.15% | -70.15% |
| Gross Margin | - | - | - | - | 81.01% | 90.98% | 87.99% | 89.73% | 89.73% | 89.41% |
| Net Margin | - | - | - | - | -2207.1% | -766.22% | -238.52% | -200.27% | -103.57% | -93.84% |
| Debt / Equity | - | - | 0.01x | 0.02x | 0.01x | 0.01x | 0.01x | 0.02x | 1.77x | 1.77x |
| Interest Coverage | - | - | - | - | - | -33.82x | -12.25x | -11.63x | -8.52x | -12.41x |
| FCF Conversion | 0.87x | 0.84x | 0.91x | 0.93x | 2.10x | 0.96x | 0.74x | 0.44x | 0.59x | 0.59x |
| Revenue Growth | - | - | - | - | - | 649.46% | 227.56% | 68.06% | 45.83% | 58.67% |
RYTM SEC Filings & Documents
Rhythm Pharmaceuticals, Inc. (RYTM) SEC filings — annual & quarterly reports (10-K, 10-Q)
RYTM Frequently Asked Questions
Rhythm Pharmaceuticals, Inc. (RYTM) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Rhythm Pharmaceuticals, Inc. (RYTM) reported $217.2M in revenue for fiscal year 2025.
Rhythm Pharmaceuticals, Inc. (RYTM) grew revenue by 45.8% over the past year. This is strong growth.
Rhythm Pharmaceuticals, Inc. (RYTM) reported a net loss of $203.8M for fiscal year 2025.
Dividend & Returns
Rhythm Pharmaceuticals, Inc. (RYTM) does not currently pay a meaningful dividend. The company may be reinvesting profits for growth.
Rhythm Pharmaceuticals, Inc. (RYTM) has a return on equity (ROE) of -129.5%. Negative ROE indicates the company is unprofitable.
Rhythm Pharmaceuticals, Inc. (RYTM) had negative free cash flow of $120.5M in fiscal year 2025, likely due to heavy capital investments.
Explore More RYTM
Rhythm Pharmaceuticals, Inc. (RYTM) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates